Results 31 to 40 of about 3,692,716 (212)

Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms. [PDF]

Int J Lab Hematol
ABSTRACT Introduction RUNX1 is a commonly mutated transcriptional regulator of hematopoiesis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mutated RUNX1 (mRUNX1) may associate with cross‐lineage immunophenotypic aberrancy, presenting potential complications for blast lineage assignment at diagnosis. Methods Clinical and laboratory
Xia YH, McGinnis E.
europepmc   +2 more sources

Optimization of the indications for allogeneic stem cell transplantation in Acute Myeloid Leukemia based on interactive diagnostic strategies [PDF]

, 2011
The indications for allogeneic stem cell transplantation (SCT) in Acute Myeloid Leukemia (AML) represent a real challenge due to the clinical and genetic heterogeneity of the disorder.
Hartwig, Maite, Zander, Axel R., Haferlach, Torsten, Fehse, Boris, Bacher, Ulrike, Kröger, Nicolaus   +5 more
core   +1 more source

Exploring downstream pathways of aberrantly activated kinases for targeted leukemia therapy [PDF]

, 2008
Genetic alterations resulting in uncontrolled protein tyrosine kinases (PTKs) activity are frequently found in leukemia and in human solid cancers. Although the development of small molecule kinase inhibitors has revolutionized therapy for PTKinduced ...
Gasser, Christelle
core   +1 more source

CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis

Advances in Hematology, 2009
The cAMP response element-binding protein (CREB) is a nuclear transcription factor downstream of cell surface receptors and mitogens that is critical for normal and neoplastic hematopoiesis.
Salemiz Sandoval, Martina Pigazzi, Kathleen M. Sakamoto   +2 more
doaj   +1 more source

Intrachromosomal amplification of chromosome 21 (iAMP21) detected by ETV6/RUNX1 FISH screening in childhood acute lymphoblastic leukemia: a case report

Revista Brasileira de Hematologia e Hemoterapia, 2013
Chromosome abnormalities that usually define high-risk acute lymphoblastic leukemia are the t(9;22)/ breakpoint cluster region protein-Abelson murine leukemia viral oncogene homolog 1, hypodiploid with < 44 chromosomes and 11q23/ myeloid/lymphoid ...
Daniela Ribeiro Ney Garcia, Alejandro Mauricio Arancibia, Raul C. Ribeiro, Marcelo Gerardin Poirot Land, Maria Luiza Macedo Silva   +4 more
doaj   +1 more source

Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis

Haematologica, 2020
RAS-signaling mutations induce the myelomonocytic differentiation and proliferation of hematopoietic stem and progenitor cells. Moreover, they are important players in the development of myeloid neoplasias.
Veronica Caraffini, Olivia Geiger, Angelika Rosenberger, Stefan Hatzl, Bianca Perfler, Johannes L. Berg, Clarice Lim, Herbert Strobl, Karl Kashofer, Silvia Schauer, Christine Beham-Schmid, Gerald Hoefler, Klaus Geissler, Franz Quehenberger, Walter Kolch, Dimitris Athineos, Karen Blyth, Albert Wölfler, Heinz Sill, Armin Zebisch   +19 more
doaj   +1 more source

Genetic Ablation and Multi‐Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models

Advanced Science, EarlyView.
Genetic ablation of Cep55 in Pten‐deficient mouse models delays tumorigenesis. Integrated multi‐omics analyses (proteomics, phosphoproteomics, and spatial transcriptomics) reveal that CEP55 regulates oncogenic signaling (RAS/ERK, PI3K/AKT), integrin/FAK‐mediated adhesion, extracellular matrix (ECM) remodeling, and endocytosis.
Behnam Rashidieh, Yuanhao Yang, Amanda Louise Bain, Phillip Theron, Catharina Vosloo, Sahar Keshvari, Parinaz Ahangar, Brydie Bowden, Simon M. Tria, Ben B. Wang, Sandra Isenmann, Nicholas J. Westra van Holthe, Zherui Xiong, Hani Vu, Sowmya Sharma, Asmerom Sengal, J. Alejandro Lopez, John Finnie, Antonella Papa, Pascal H.G. Duijf, Quan Nguyen, Pirjo M. Apaja, Kum Kum Khanna   +22 more
wiley   +1 more source

Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach [PDF]

, 2010
Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core   +1 more source

GABP is necessary for stem/progenitor cell maintenance and myeloid differentiation in human hematopoiesis and chronic myeloid leukemia

Stem Cell Research, 2016
Maintenance of hematopoietic stem cells and their potential to give rise to progenitors of differentiated lymphoid and myeloid cells are accomplished by a network of regulatory processes. As a part of this network, the heteromeric transcription factor GA-
Georgi Manukjan, Tim Ripperger, Letizia Venturini, Michael Stadler, Gudrun Göhring, Axel Schambach, Brigitte Schlegelberger, Doris Steinemann   +7 more
doaj   +1 more source

Neoantigens in Hematologic Malignancies

Frontiers in Immunology, 2020
T cell cancer neoantigens are created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface.
Melinda A. Biernacki, Melinda A. Biernacki, Marie Bleakley, Marie Bleakley   +3 more
doaj   +1 more source